Ovarian cancer metastasis study identifies important protein with potential as diagnostic tool and treatment option
Advanced ovarian cancer most commonly metastasizes to the omentum, a layer of fatty tissue that wraps around and protects internal organs in the abdomen, but the reasons for this have not been well-understood. In a new study, MD Anderson researchers discovered that a protein called omentin, or ITLN1, works to prevent metastasis of the cancer cells, but it is lost as the cancer develops.
Their preclinical findings, published in...
BIA-ALCL study shows multi-team treatment key to achieving best outcomes
A team of researchers from across five disciplines at MD Anderson recently published the largest prospective study on breast implant associated...
Study shows Enhanced Recovery After Surgery lowers pain and opioid use for lung cancer patients
MD Anderson surgeons have found a way to reduce pain and opioid use for lung cancer patients undergoing a lung...
Twelve MD Anderson researchers honored with 2020 AACR Team Science Awards
The American Association for Cancer Research (AACR) is recognizing the founding members of The Cancer Genome Atlas (TCGA) and the current project team with 2020 AACR Team Science Awards. These teams will be honored during the AACR Virtual Annual Meeting II on June 24.
The Cancer Genome Atlas was launched in 2006 as a joint endeavor between the National Cancer Institute (NCI) and the National Human...
Brain metastases recruit suppressive immune cells via novel pathway to facilitate their growth
MD Anderson researchers have discovered that metastatic cancer cells in the brain upregulate expression of the EZH2 gene to activate a previously...
Cancer-associated fibroblasts fuel breast cancer growth
Researchers at MD Anderson have discovered that cancer-associated fibroblasts (CAF) help fuel the growth of breast tumors. Their findings...
ASCO: Palliative and supportive care interventions increase comfort in advanced cancer patients
Two studies presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting highlighted MD Anderson’s commitment to holistic...
ASCO: Updated targeted therapy clinical trials results continue to show improved outcomes for advanced colorectal and bladder cancers
Updated results from two MD Anderson clinical trials presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting indicate...
ASCO: Developing effective combination therapies for leukemia
Findings from three studies led by researchers at MD Anderson suggest that new combination therapies are safe and effective against various...
ASCO: Advances in T cell therapies for lymphomas
Two studies led by MD Anderson researchers explore advancements in CAR T cell therapy for non-Hodgkin lymphomas. CAR T cell therapy is commonly...
ASCO: Studies pave the way on immunotherapy clinical trials for rare, aggressive cancers
Several MD Anderson-led studies at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting focus on using immunotherapy to provide...
ASCO: Emerging approaches to improve immunotherapy for cancer treatment
Brian Odle has now overcome four cancer diagnoses in his life, thanks to inheriting a mutation in the TP53 gene. This inherited condition...
ASCO: Emerging targeted therapies show signs of clinical activity across multiple cancer types
Julia Pitts tried all the standard treatment options with her local physicians after she was diagnosed with metastatic uterine cancer in 2015...
ASCO: Studies show advances in treatment and understanding of BRCA-associated and triple-negative breast cancer
Mutations in the BRCA 1 or 2 genes significantly increase an individual’s risk of developing breast cancer, as well as several other cancer...
Study shows potential for digital microscopy for real-time accurate evaluation to aid acquisition of high quality tissue
Strategies to procure high-quality core-needle biopsy (CNB) specimens are critical for making basic tissue diagnoses and for ancillary testing...
Larotrectinib shows marked responses with NTRK gene fusions, limited response in non-fusion mutations
In an analysis of three clinical trials, the targeted therapy larotrectinib resulted in a 79% overall response rate and median overall survival...
Genomic study of brain metastases sheds light on unique features relative to primary tumors
A deep sequencing study of brain metastases from MD Anderson revealed many similarities but also distinct differences relative to the primary...
Phase I clinical trial shows WNT974 in combination with spartalizumab well tolerated for advanced solid tumor patients
An MD Anderson Phase I clinical trial demonstrated that a combination therapy using WNT974, a drug that targets the WNT pathway in cancer,...
Study shows naproxen promotes immune activation in Lynch syndrome patients
A Phase I chemoprevention clinical trial led by MD Anderson researchers found that naproxen, an over-the-counter anti-inflammatory drug, is...
AACR: Ovarian cancer clinical trial shows effects, safety of upfront immunotherapy and chemotherapy for advanced disease
Results from a clinical trial led by MD Anderson researchers showed that combining the immunotherapy checkpoint inhibitor drug durvalumab...
Ovarian cancer analysis identifies potential treatment biomarkers
MD Anderson researchers have identified potential biomarkers for the response of high-grade serous ovarian cancers (HGSC) to surgical resection...
Chemotherapy/immunotherapy combination thwarts glioblastoma in pre-clinical research
Triple combination therapy kills glioblastoma in mice by putting an “eat me” signal to the immune system on the surface of the brain tumor...
Immunotherapy combination stifles pancreatic cancer in mouse models
Combining two immunotherapies caused tumor rejection in mouse models of pancreatic cancer and provided long-term immune memory that prevented...
Acute myeloid leukemia’s minimal residual disease targeted by Moon Shot
In patients with leukemia, complete remission after treatment is currently defined by the absence of cancer cells in a bone marrow biopsy...
Triple-negative breast cancer clinical trial allies with community oncologists
Triple-negative breast cancer (TNBC) is an aggressive disease that makes up roughly 15% to 20% of breast cancer diagnoses. Standard chemotherapy...
Scientific communication predicts research career intention
“Trainees at the Ph.D. and postdoctoral level are leaving the academic research track at alarming rates, and disproportionately if they’re...
For non-small cell lung cancer, T cell repertoire in lungs affects survival
Surveying the landscape of T cell presence and activity across the lungs of patients treated for localized non-small cell lung cancer, researchers...
New guidelines for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) provide diagnosis guidance
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon form of ALCL that was first reported in 1996. The U.S....
Heated post-surgical chemotherapy improves survival for stage IV stomach cancer
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a type of cancer treatment in which surgeons apply heated chemotherapy...
Extending cervical cancer prevention around the world
While U.S. cervical cancer rates have fallen by 70% since the 1950s thanks to the Pap test and national screening programs, the disease...
Ovarian Cancer Moon Shot works to broaden immunotherapy impact
Immunotherapies have brought the potential for long-term remission and even cures to patients with many cancer types, but the benefits have...
Hussein Tawbi named to President’s Council on Science and Technology
President Donald Trump today announced his intent to appoint Hussein Tawbi, M.D., Ph.D., associate professor and deputy chairman of Melanoma...
Making CAR T cell therapy more effective for B-cell lymphoma treatment
Chimeric antigen receptor (CAR) T cells were approved by the Food and Drug Administration (FDA) to treat relapsed and refractory large B-cell...
MD Anderson accelerates cellular therapy programs by buying state-of-art manufacturing facility
Cellular therapies have emerged as an effective new therapy for patients with certain types of cancer, and MD Anderson has played an important...
Tumor cells form networks to penetrate the brain
Researchers from MD Anderson have revealed how glioma cells move and infiltrate the brain, providing a new potential treatment pathway to...
JAMA study reveals side effect impact of localized prostate cancer treatments
A study published in JAMA comparing adverse event outcomes by treatment type for patients with localized prostate cancer reveals most...
ECLIPSE looks to extinguish leukemia by uncovering new treatment targets
MD Anderson has created a new research platform to drive the discovery of new therapeutic agents for patients with leukemia by investigating...